Innovating Advanced Treatments for Your Glaucoma Patients: Diagnostics, Novel Therapies, and Surgical Options
Supported by unrestricted educational grants from Aerie Pharmaceuticals, Alcon Laboratories Inc., Allergan, Carl Zeiss Meditec, and Glaukos
Richard A. Lewis, MD
Douglas J. Rhee, MD
Nathan Radcliffe, MD
Brian A. Francis, MD
6:30 AM Welcome and Review of Pre-Registrant Survey Data, Opening ARS, Introduction of Case Study – Richard A. Lewis, MD
6:40 AM Discussion on Advanced Diagnostic Measurements for Better Disease Management – Douglas J. Rhee, MD
6:50 AM Panel Discussion and Audience Response System Assessment – Richard A. Lewis, MD
6:55 AM Next Generation Glaucoma Therapies and Baselines for Success – Nathan Radcliffe, MD
7:05 AM Update on Clinical Development Programs, Panel Discussion and Audience Response System Assessment – Richard A. Lewis, MD
7:15 AM New Microsurgical Techniques for the Long-Term Treatment of Glaucoma – Brian A. Francis, MD
7:25 AM Panel Discussion and Final Audience Response System Assessment – Richard A. Lewis, MD
7:30 AM Conclude
Ophthalmologists who attend this course will:
- Describe the issue of treatment compliance in the management of glaucoma and its impact on patient outcomes.
- Assess the impact of novel pharmaceutical options – including new combination drugs and drug delivery systems – on treatment compliance among patients with glaucoma and their corresponding effect on treatment outcomes.
- Identify the latest scientific information on MIGS, both with regards to study results, and evolving surgical techniques to maximize the outcomes in a practice.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Society of Cataract and Refractive Surgery (ASCRS) and EyeWorld news magazine. ASCRS is accredited by the ACCME to provide continuing medical education for physicians. ASCRS takes responsibility for the content, quality, and scientific integrity of this CME activity.
The American Society of Cataract and Refractive Surgery designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
All CME activities approved for AMA PRA Category 1 Credit™ are valid for recognition by the European Accreditation Council for Continuing Medical Education (EACCME). Physicians not licensed in the U.S. who participate in this CME activity are eligible for AMA PRA Category 1 Credit™.
Attendees registered as exhibitors, spouses, and guests are not eligible for CME credits.
Notice of Off-Label Use Presentations
This program may include presentations on drugs or devices or uses of drugs or devices that may not have been approved by the Food and Drug Administration (FDA) or have been approved by the FDA for specific uses only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or device he/she wishes to use in clinical practice. ASCRS is committed to the free exchange of medical education. Inclusion of any presentation in this program, including presentations of off-label uses, does not imply an endorsement by ASCRS of the uses, products, or techniques presented.
ASCRS fully complies with the legal requirements of the Americans with Disabilities Act (ADA) and the rules and regulations thereof. ASCRS also requires ADA compliance from its contracted vendors and facilities. Any participant in this educational program who requires special accommodation or services should contact an ASCRS or EyeWorld staff member onsite.